½ÃÀ庸°í¼­
»óǰÄÚµå
1604719

¼¼°èÀÇ ÀçÅà ¾à¹° ³²¿ë °Ë»ç ½ÃÀå :Á¦Ç° À¯Çü, ¾à¹°, À¯Åë ä³Îº°¿¹Ãø(2025-2030³â)

At-home Drug of Abuse Testing Market by Product (Blood-Based Testing Kits, Breathalyzer Testing Kits, Hair-Based Testing Kits), Test Type (Cups, Strips), Drug, Distribution Channel - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 181 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

ÀçÅà ¾à¹° ³²¿ë °Ë»ç ½ÃÀåÀº 2023³â¿¡ 26¾ï 8,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2024³â¿¡´Â 28¾ï 8,000¸¸ ´Þ·¯¿¡ µµ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR) 7.25%·Î ¼ºÀåÇÏ¿©, 2030³â¿¡´Â 43¾ï 8,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÀçÅà ¾à¹° ³²¿ë °Ë»ç´Â °³ÀÎÀÌ Æí¸®ÇÏ°Ô ºÒ¹ý ¾à¹°À» °Ë»çÇÒ ¼ö ÀÖ´Â ½ÃÆÇ¿ë ŰƮ¸¦ °¡¸®Åµ´Ï´Ù.ÀÇ °Ë»ç´Â ÄÄÇöóÀÌ¾ð½º¿Í ¾ÈÀüÀ» º¸ÀåÇϱâ À§ÇØ °¡Á¤, Á÷Àå, ÀçȰ¼¾ÅÍ, ¹ý ÁýÇà ±â°ü µî¿¡¼­ ÀÀ¿ëµÇ°í ÀÖ½À´Ï´Ù. °í¿ëÁÖ, º¸È£°üÂû°ü, ÀÇ·á Á¦°øÀÚ µîÀÌ Æ÷ÇԵǾî ÀÖÀ¸¸ç ±â¹Ð¼º°ú ½Å¼ÓÇÑ °á°ú¸¦ ¿ì¼±Çϰí ÀÖ½À´Ï´Ù. Áõ°¡ÇÏ°í °Ë»ç ±â¼úÀÇ Áøº¸¿¡ ÀÇÇÑ Á¤¹Ðµµ¿Í »ç¿ëÀÇ ¿ëÀ̼ºÀÇ Çâ»óÀÌ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ±»ÀÌ, À¯¸®ÇÑ ±âȸ¸¦ °¡Á®¿À°í ÀÖ½À´Ï´Ù¸¸, ±ÔÁ¦ÀÇ ºÒÈ®½Ç¼º, °á°úÀÇ Á¤È®¼º, À§¾ç¼º¿¡ ´ëÇÑ ¿ì·Á, ƯÁ¤ ¾à¹°ÀÇ °ËÃâ ÇÑ°è µîÀÇ °úÁ¦°¡ ä¿ëÀÇ ¹æÇذ¡ µÇ°í ÀÖ½À´Ï´Ù. Áö¿ªº°·Î ´ÜÆíÈ­µÈ ±ÔÁ¦ ȯ°æÀº Á¦Á¶¾÷üÀÇ ÄÄÇöóÀ̾𽺠Àå¾Ö¹°ÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù. ·çŸÀÓÀÇ °á°ú¿Í ÁöħÀ» Á¦°øÇÔÀ¸·Î½á »ç¿ëÀÚ °æÇèÀ» Çâ»ó½ÃŰ´Â µ¥ ÀáÀçÀûÀÎ ±âȸ°¡ ÀÖ½À´Ï´Ù. À» È®ÀåÇÏ´Â °Í °°½À´Ï´Ù. ¶ÇÇÑ, ¹ÙÀÌ¿À ¼¾¼­ ±â¼ú°ú ºñ ħ½ÀÀûÀÎ °Ë»ç ¹æ¹ýÀÇ ¿¬±¸´Â Áß¿äÇÑ Çõ½ÅÀ» °¡Á®¿Ã ¼ö ÀÖ½À´Ï´Ù.½ÃÀåÀÇ °æÀïÀº Ä¡¿­ÇØÁö°í ÀÖÁö¸¸, ±âÁ¸ÀÇ Áø´Ü¾à ±â¾÷¿¡¼­ Æ´»õ ½ÅÈï ±â¾÷¿¡ À̸£±â±îÁö ¼ö¸¹Àº ±â¾÷ÀÌ ÁøÀÔÇϰí ÀÖÀ¸¸ç, ½ÃÀåÀº ¼¼ºÐÈ­µÇ°í ÀÖ½À´Ï´Ù. Àü·«Àû ÆÄÆ®³Ê½Ê°ú °¡Á¤¿ë °Ë»ç ŰƮÀÇ Á߿伺°ú ½Å·Ú¼ºÀ» ¼ÒºñÀÚ¿¡°Ô °è¸ùÇϱâ À§ÇÑ °è¹ß ÇÁ·Î±×·¥¿¡ ÁÖ·ÂÇØ¾ß ÇÕ´Ï´Ù. ±âÁØ Áؼö¸¦ º¸ÀåÇϱâ À§ÇØ ±ÔÁ¦ ±â°ü°úÀÇ Çù·ÂÀº Å« À庮À» ±Øº¹Çϱâ À§ÇØ ÇʼöÀûÀÔ´Ï´Ù. ±â¾÷Àº ºò µ¥ÀÌÅÍ ºÐ¼®À» Ȱ¿ëÇÏ¿© »ç¿ë ÆÐÅÏÀ» ÃßÀûÇϰí Á¦Ç° °³¹ßÀ» °³¼±ÇÕ´Ï´Ù ±×·¯¸é »õ·Î¿î ¼ÒºñÀÚÀÇ ¿ä±¸¿Í ±âÈ£¿¡ È¿°úÀûÀ¸·Î ´ëÀÀÇÒ ¼ö ÀÖµµ·Ï ÇØ¾ß ÇÕ´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁسâ(2023) 26¾ï 8,000¸¸ ´Þ·¯
ÃßÁ¤³â(2024) 28¾ï 8,000¸¸ ´Þ·¯
¿¹Ãø³â(2030) 43¾ï 8,000¸¸ ´Þ·¯
º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR)(%) 7.25%

½ÃÀå ¿ªÇÐ : ±Þ¼ÓÈ÷ ÁøÈ­ÇÏ´Â ÀçÅà ¾à¹° ³²¿ë °Ë»ç ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ® °ø°³

ÀçÅà ¾à¹° ³²¿ë °Ë»ç ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ ÀÛ¿ë¿¡ ÀÇÇØ º¯¸ð¸¦ ÀÌ·ç°í ÀÖ½À´Ï´Ù. »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ ¾òÀ» ¼ö ÀÖ½À´Ï´Ù ÀÌ·¯ÇÑ µ¿ÇâÀ» Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ °æ°¨ÇÒ ¼ö ÀÖÀ½°ú µ¿½Ã¿¡ ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ë°ú ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ»º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • ºÒ¹ý ¾à¹°ÀÇ »ç¿ë°ú »ý»ê Áõ°¡
    • ¾à¹° ³²¿ëÀ» ÁÙÀ̱â À§ÇÑ Á¤ºÎÀÇ ÀÌ´Ï¼ÅÆ¼ºê
    • ¾à¹° »ý»ê È®´ë¿¡ ÀÇÇÑ È¿°úÀûÀÎ °Ë»ç ´ëÃ¥ÀÇ Çʿ伺
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ¼Ò·®ÀÇ Æ¯¼ö ¾à¹°À» °ËÃâÇÒ ¼ö ¾ø´Â °Ë»ç Á¦Ç°
  • ½ÃÀå ±âȸ
    • »õ·Î¿î ÀçÅà ¾à¹° ³²¿ë °Ë»ç ÀåÄ¡ÀÇ ±â¼úÀû Áøº¸¿Í °³¹ß
    • ÀçÅà ¾à¹° ³²¿ë °Ë»ç µð¹ÙÀ̽ºÀÇ ¿¬±¸ °³¹ß Ȱµ¿¿¡ ´ëÇÑ ÅõÀÚ
  • ½ÃÀåÀÇ °úÁ¦
    • ÀçÅà ¾à¹° ³²¿ë °Ë»ç µð¹ÙÀ̽ºÀÇ ÀÎÁöµµ ºÎÁ·

Porter's Five Forces : ÀçÅà ¾à¹° ³²¿ë °Ë»ç ½ÃÀåÀ» Ž»öÇÏ´Â Àü·« µµ±¸

Porter's Five Forces Framework´Â ÀçÅà ¾à¹° ³²¿ë °Ë»ç ½ÃÀå °æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. Porter's Five Forces Framework´Â ±â¾÷ÀÇ °æÀï·ÂÀ» Æò°¡Çϰí Àü·«Àû ±âȸ¸¦ ޱ¸ÇÏ´Â ¸íÈ®ÇÑ ±â¼úÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÀλçÀÌÆ®À» ÅëÇØ ±â¾÷Àº ÀÚ»çÀÇ °­Á¡À» Ȱ¿ëÇÏ°í ¾àÁ¡À» ÇØ°áÇϰí ÀáÀçÀûÀÎ °úÁ¦¸¦ ÇÇÇÔÀ¸·Î½á º¸´Ù °­ÀÎÇÑ ½ÃÀå¿¡¼­ÀÇ Æ÷Áö¼Å´×À» È®º¸ÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : ÀçÅà ¾à¹° ³²¿ë °Ë»ç ½ÃÀå¿¡¼­ ¿ÜºÎ·ÎºÎÅÍÀÇ ¿µÇâ ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº ÀçÅà ¾à¹° ³²¿ë °Ë»ç ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ»ÇÕ´Ï´Ù. Á¤Ä¡Àû, °æÁ¦Àû, »çȸÀû, ±â¼úÀû, ¹ýÀû, ȯ°æÀû ¿äÀÎ ºÐ¼®Àº ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇÕ´Ï´Ù. PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀûÀÎ À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®À» ÅëÇØ ±â¾÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ¼±È£, °æÁ¦ µ¿ÇâÀÇ º¯È­¸¦ ¿¹ÃøÇÏ°í ¾ÕÀ¸·Î ¿¹»óµÇ´Â Àû±ØÀûÀÎ ÀÇ»ç °áÁ¤À» ÇÒ Áغñ°¡ °¡´ÉÇÕ´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® ÀçÅà ¾à¹° ³²¿ë °Ë»ç ½ÃÀå °æÀï ±¸µµ ÆÄ¾Ç

ÀçÅà ¾à¹° ³²¿ë °Ë»ç ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¼öÀÍ, °í°´ ±â¹Ý, ¼ºÀå·ü µî ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© °æÀï Æ÷Áö¼Å´×À» ¹àÈú ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®À» ÅëÇØ ½ÃÀå ÁýÁß, ´ÜÆíÈ­, ÅëÇÕ µ¿ÇâÀ» ¹àÇô³»°í º¥´õµéÀº °æÀïÀÌ Ä¡¿­ÇØÁö´Â °¡¿îµ¥ ÀÚ»çÀÇ ÁöÀ§¸¦ ³ôÀÌ´Â Àü·«Àû ÀÇ»ç °áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ Áö½ÄÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º : ÀçÅà ¾à¹° ³²¿ë °Ë»ç ½ÃÀå¿¡¼­ °ø±Þ¾÷üÀÇ ¼º´É Æò°¡

FPNV Positioning Matrix´Â °¡Á¤¿ë ¾à¹° ³²¿ë °Ë»ç ½ÃÀå¿¡¼­ °ø±Þ¾÷ü¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ÀÌ Çà·ÄÀ» ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº °ø±Þ¾÷üÀÇ ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±âÁØÀ¸·Î Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ¸Â´Â ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç °áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù. ³× °¡Áö »çºÐ¸éÀ» ÅëÇØ °ø±Þ¾÷ü¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ¼¼ºÐÈ­ÇÏ¿© Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê ¹× ¼Ö·ç¼ÇÀ» ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù.

Àü·«ºÐ¼® ¹× Ãßõ ÀçÅþ๰ ³²¿ë°Ë»ç½ÃÀå¿¡¼­ ¼º°øÀ» À§ÇÑ ±æÀ» ±×¸³´Ï´Ù.

ÀçÅà ¾à¹° ³²¿ë °Ë»ç ½ÃÀåÀÇ Àü·« ºÐ¼®Àº ½ÃÀå¿¡¼­ÀÇ ÇÁ·¹Á𽺠°­È­¸¦ ¸ñÇ¥·Î ÇÏ´Â ±â¾÷¿¡ ÇʼöÀûÀÎ ¿ä¼ÒÀÔ´Ï´Ù. ÀÌ Á¢±Ù¹ýÀ» ÅëÇØ °æÀï ±¸µµ¿¡¼­ °úÁ¦¸¦ ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö ÀÖ´Â ½Ã½ºÅÛÀ» ±¸ÃàÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â ½ÃÀåÀÇ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõ : ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·Â Æò°¡.

2. ½ÃÀå °³Ã´µµ : ½ÅÈï ½ÃÀåÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇÏ°í ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡ÇÏ¸ç ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù¾çÈ­ : ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä Áøº¸, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú Áøº¸ µîÀ» °ËÁõÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÃÖ÷´Ü ±â¼ú, R&D Ȱµ¿, Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

¶ÇÇÑ ÀÌÇØ°ü°èÀÚ°¡ ÃæºÐÇÑ Á¤º¸¸¦ ¾ò°í ÀÇ»ç°áÁ¤À» ÇÒ ¼ö ÀÖµµ·Ï Áß¿äÇÑ Áú¹®¿¡ ´ë´äÇϰí ÀÖ½À´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå ¿¹ÃøÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹® ¹× Áö¿ªÀº ¾îµðÀԴϱî?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5. º¥´õ ½ÃÀå ÁøÀÔ, ö¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
      • ºÒ¹ý ¾à¹°ÀÇ »ç¿ë°ú »ý»ê Áõ°¡
      • ¾à¹° ³²¿ëÀ» ÁÙÀ̱â À§ÇÑ Á¤ºÎÀÇ ÀÌ´Ï¼ÅÆ¼ºê
      • ÀǾàǰ »ý»ê È®´ë¿¡´Â È¿°úÀûÀÎ °Ë»ç ´ëÃ¥ÀÌ ÇÊ¿ä
    • ¾ïÁ¦¿äÀÎ
      • Á¦Ç°À» °Ë»çÇÏ¿© ¹Ì·®ÀÇ Æ¯¼ö ¾à¹°À» °ËÃâÇÒ ¼ö ¾ø½À´Ï´Ù
    • ±âȸ
      • ±â¼úÀÇ Áøº¸¿Í »õ·Î¿î ÀçÅà ¾à¹° ³²¿ë °Ë»ç µð¹ÙÀ̽ºÀÇ °³¹ß
      • ÀçÅà ¾à¹° ³²¿ë °Ë»ç µð¹ÙÀ̽ºÀÇ ¿¬±¸ °³¹ß Ȱµ¿¿¡ ´ëÇÑ ÅõÀÚ
    • °úÁ¦
      • ÀçÅà ¾à¹° ³²¿ë °Ë»ç ÀåÄ¡ÀÇ ÀÎ½Ä ºÎÁ·
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
  • Porter's Five Forces ºÐ¼®
  • PESTEL ºÐ¼®
    • Á¤Ä¡Àû
    • °æÁ¦
    • »ç±³
    • ±â¼úÀû
    • ¹ý·ü»ó
    • ȯ°æ

Á¦6Àå ÀçÅà ¾à¹° ³²¿ë °Ë»ç ½ÃÀå : Á¦Ç°º°

  • Ç÷¾× °Ë»ç ŰƮ
  • À½ÁÖ °¨Áö±â °Ë»ç ŰƮ
  • ¸ð¹ß °Ë»ç ŰƮ
  • Ÿ¾× °Ë»ç ŰƮ
  • ¼Òº¯ °Ë»ç ŰƮ

Á¦7Àå ÀçÅà ¾à¹° ³²¿ë °Ë»ç ½ÃÀå : Å×½ºÆ® À¯Çüº°

  • ÄÅ
  • ½ºÆ®¸³

Á¦8Àå ÀçÅà ¾à¹° ³²¿ë °Ë»ç ½ÃÀå ¾à¹°º°

  • ¾ËÄÚ¿Ã
  • ¾ÏÆäŸ¹Î
  • º¥Á¶µð¾ÆÁ¦ÇÉ
  • ÄÚÄ«ÀÎ
  • ¸¶¸®È­³ª
  • ¿ÀÇÇ¿ÀÀ̵å

Á¦9Àå ÀçÅà ¾à¹° ³²¿ë °Ë»ç ½ÃÀå : À¯Åë ä³Îº°

  • ¿ÀÇÁ¶óÀÎ
  • ¿Â¶óÀÎ

Á¦10Àå ¾Æ¸Þ¸®Ä«ÀÇ ÀçÅà ¾à¹° ³²¿ë °Ë»ç ½ÃÀå

  • ¾Æ¸£ÇîÆ¼³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦11Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ÀçÅà ¾à¹° ³²¿ë °Ë»ç ½ÃÀå

  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦12Àå À¯·´, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ÀçÅà ¾à¹° ³²¿ë °Ë»ç ½ÃÀå

  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍŰ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
  • ¿µ±¹

Á¦13Àå °æÀï ±¸µµ

  • ½ÃÀå Á¡À¯À² ºÐ¼®(2023³â)
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º(2023³â)
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®
  • Àü·« ºÐ¼®°ú Á¦¾È

±â¾÷ ¸ñ·Ï

  • Abbott Laboratories
  • AccuBioTech Co. Ltd.
  • Accuquik by AdvaCare Pharma USA
  • Atlas Medical GmbH
  • BioMerieux, Inc.
  • Biopanda Reagents Ltd.
  • BTNX Inc.
  • Confirm BioSciences
  • Dragerwerk AG & Co. KGaA
  • Exploro Products
  • Identify Diagnostics by Medical Distribution Group, Inc.
  • Innovatek Medical Inc.
  • InTec Products, Inc.
  • Laboratory Corporation of America Holdings
  • McKesson Medical-Surgical
  • MyDiagnostics by Phyteos Helath Systems Inc.
  • myLAB Box Inc.
  • OraSure Technologies, Inc.
  • Phamatech Inc. by Caris Life Sciences
  • Psychemedics Corporation
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
  • UCP Biosciences Inc.
  • Vitrosens Biotechnology
  • Xiamen Boson Biotech Co. Ltd.
BJH 24.12.16

The At-home Drug of Abuse Testing Market was valued at USD 2.68 billion in 2023, expected to reach USD 2.88 billion in 2024, and is projected to grow at a CAGR of 7.25%, to USD 4.38 billion by 2030.

At-home drug of abuse testing refers to commercially available kits enabling individuals to test for illicit drugs privately and conveniently. They are crucial for early detection and prevention of drug misuse, facilitating immediate intervention and care. These tests find applications in households, workplaces, rehabilitation centers, and law enforcement to ensure compliance and safety. Key end-users include parents, employers, probation officers, and healthcare providers prioritizing confidentiality and rapid results. Market growth is fueled by the rising prevalence of drug abuse, increasing awareness about drug testing's importance, and advancements in testing technology which have enhanced accuracy and ease of use. Moreover, the expanding legality of cannabis in various regions stirs demand for THC-specific testing products, presenting lucrative opportunities. Nonetheless, challenges like regulatory uncertainties, concerns over result accuracy, false positives, and specific drugs' detection limitations hinder adoption. A fragmented regulatory environment across regions may also create compliance hurdles for manufacturers. The potential opportunity lies in integrating digital technologies, like mobile apps, to offer real-time results and guidance, improving user experience. Innovating multi-drug testing kits that maintain precision across different substances and drugs will also widen market reach. Furthermore, research into biosensor technology and non-invasive testing methods could yield significant innovations. The nature of the market is competitive yet fragmented with numerous players ranging from established diagnostics companies to niche startups. To thrive, companies must focus on strategic partnerships for distribution and awareness programs to educate consumers on the importance and reliability of at-home testing kits. Collaboration with regulatory bodies to ensure standards compliance will be vital in surpassing significant barriers. Businesses should leverage big data analytics to track usage patterns and improve product developments, ensuring they meet emerging consumer needs and preferences effectively.

KEY MARKET STATISTICS
Base Year [2023] USD 2.68 billion
Estimated Year [2024] USD 2.88 billion
Forecast Year [2030] USD 4.38 billion
CAGR (%) 7.25%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving At-home Drug of Abuse Testing Market

The At-home Drug of Abuse Testing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing use and production of illicit drugs
    • Government initiatives to reduce drug abuse
    • Expansion of drug production necessitates effective test measures
  • Market Restraints
    • Inability of testing products to detect small amounts of special drugs
  • Market Opportunities
    • Technological advancement and development of novel at-home drug of abuse testing devices
    • Investment in R&D activities for at-home drug of abuse testing devices
  • Market Challenges
    • Lack of awareness of at-home drug of abuse testing devices

Porter's Five Forces: A Strategic Tool for Navigating the At-home Drug of Abuse Testing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the At-home Drug of Abuse Testing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the At-home Drug of Abuse Testing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the At-home Drug of Abuse Testing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the At-home Drug of Abuse Testing Market

A detailed market share analysis in the At-home Drug of Abuse Testing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the At-home Drug of Abuse Testing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the At-home Drug of Abuse Testing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the At-home Drug of Abuse Testing Market

A strategic analysis of the At-home Drug of Abuse Testing Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the At-home Drug of Abuse Testing Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AccuBioTech Co., Ltd., Accuquik by AdvaCare Pharma USA, Atlas Medical GmbH, BioMerieux, Inc., Biopanda Reagents Ltd., BTNX Inc., Confirm BioSciences, Dragerwerk AG & Co. KGaA, Exploro Products, Identify Diagnostics by Medical Distribution Group, Inc., Innovatek Medical Inc., InTec Products, Inc., Laboratory Corporation of America Holdings, McKesson Medical-Surgical, MyDiagnostics by Phyteos Helath Systems Inc., myLAB Box Inc., OraSure Technologies, Inc., Phamatech Inc. by Caris Life Sciences, Psychemedics Corporation, Siemens Healthineers AG, Thermo Fisher Scientific Inc., UCP Biosciences Inc., Vitrosens Biotechnology, and Xiamen Boson Biotech Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the At-home Drug of Abuse Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Blood-Based Testing Kits, Breathalyzer Testing Kits, Hair-Based Testing Kits, Saliva-Based Testing Kits, and Urine-Based Testing Kits.
  • Based on Test Type, market is studied across Cups and Strips.
  • Based on Drug, market is studied across Alcohol, Amphetamines, Benzodiazepines, Cocaine, Marijuana, and Opioids.
  • Based on Distribution Channel, market is studied across Offline and Online.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing use and production of illicit drugs
      • 5.1.1.2. Government initiatives to reduce drug abuse
      • 5.1.1.3. Expansion of drug production necessitates effective test measures
    • 5.1.2. Restraints
      • 5.1.2.1. Inability of testing products to detect small amounts of special drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological advancement and development of novel at-home drug of abuse testing devices
      • 5.1.3.2. Investment in R&D activities for at-home drug of abuse testing devices
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of awareness of at-home drug of abuse testing devices
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. At-home Drug of Abuse Testing Market, by Product

  • 6.1. Introduction
  • 6.2. Blood-Based Testing Kits
  • 6.3. Breathalyzer Testing Kits
  • 6.4. Hair-Based Testing Kits
  • 6.5. Saliva-Based Testing Kits
  • 6.6. Urine-Based Testing Kits

7. At-home Drug of Abuse Testing Market, by Test Type

  • 7.1. Introduction
  • 7.2. Cups
  • 7.3. Strips

8. At-home Drug of Abuse Testing Market, by Drug

  • 8.1. Introduction
  • 8.2. Alcohol
  • 8.3. Amphetamines
  • 8.4. Benzodiazepines
  • 8.5. Cocaine
  • 8.6. Marijuana
  • 8.7. Opioids

9. At-home Drug of Abuse Testing Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Offline
  • 9.3. Online

10. Americas At-home Drug of Abuse Testing Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific At-home Drug of Abuse Testing Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa At-home Drug of Abuse Testing Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. AccuBioTech Co., Ltd.
  • 3. Accuquik by AdvaCare Pharma USA
  • 4. Atlas Medical GmbH
  • 5. BioMerieux, Inc.
  • 6. Biopanda Reagents Ltd.
  • 7. BTNX Inc.
  • 8. Confirm BioSciences
  • 9. Dragerwerk AG & Co. KGaA
  • 10. Exploro Products
  • 11. Identify Diagnostics by Medical Distribution Group, Inc.
  • 12. Innovatek Medical Inc.
  • 13. InTec Products, Inc.
  • 14. Laboratory Corporation of America Holdings
  • 15. McKesson Medical-Surgical
  • 16. MyDiagnostics by Phyteos Helath Systems Inc.
  • 17. myLAB Box Inc.
  • 18. OraSure Technologies, Inc.
  • 19. Phamatech Inc. by Caris Life Sciences
  • 20. Psychemedics Corporation
  • 21. Siemens Healthineers AG
  • 22. Thermo Fisher Scientific Inc.
  • 23. UCP Biosciences Inc.
  • 24. Vitrosens Biotechnology
  • 25. Xiamen Boson Biotech Co., Ltd.
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦